MacroGenics Yönetim

Yönetim kriter kontrolleri 2/4

MacroGenics CEO'su Eric Risser, Aug2025 tarihinde atandı, in görev süresi bir yıldan az. in toplam yıllık tazminatı $ 2.08M olup, şirket hissesi ve opsiyonları dahil olmak üzere 27% maaş ve 73% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.12% ine doğrudan sahiptir ve bu hisseler € 300.28K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.5 yıl ve 8.5 yıldır.

Anahtar bilgiler

Eric Risser

İcra Kurulu Başkanı

US$2.1m

Toplam tazminat

CEO maaş yüzdesi	27.01%
CEO görev süresi	less than a year
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	2.5yrs
Yönetim Kurulu ortalama görev süresi	8.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Eric Risser'un ücretlendirmesi MacroGenics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2026	n/a	n/a	-US$70m
Dec 31 2025	US$2m	US$562k	-US$75m
Sep 30 2025	n/a	n/a	-US$76m
Jun 30 2025	n/a	n/a	-US$36m
Mar 31 2025	n/a	n/a	-US$56m
Dec 31 2024	n/a	n/a	-US$67m
Sep 30 2024	n/a	n/a	-US$98m
Jun 30 2024	n/a	n/a	-US$136m
Mar 31 2024	n/a	n/a	-US$23m
Dec 31 2023	n/a	n/a	-US$9m
Sep 30 2023	n/a	n/a	US$50m
Jun 30 2023	n/a	n/a	US$7m
Mar 31 2023	n/a	n/a	-US$91m
Dec 31 2022	US$2m	US$461k	-US$120m
Sep 30 2022	n/a	n/a	-US$191m
Jun 30 2022	n/a	n/a	-US$219m
Mar 31 2022	n/a	n/a	-US$217m
Dec 31 2021	US$2m	US$428k	-US$202m
Sep 30 2021	n/a	n/a	-US$146m
Jun 30 2021	n/a	n/a	-US$129m
Mar 31 2021	n/a	n/a	-US$136m
Dec 31 2020	US$1m	US$431k	-US$130m
Sep 30 2020	n/a	n/a	-US$158m
Jun 30 2020	n/a	n/a	-US$167m
Mar 31 2020	n/a	n/a	-US$152m
Dec 31 2019	US$2m	US$388k	-US$152m

Tazminat ve Piyasa: Eric 'nin toplam tazminatı ($USD 2.08M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 800.84K ).

Tazminat ve Kazançlar: Eric şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Eric Risser (52 yo)

less than a year

Görev süresi

US$2,078,854

Tazminat

Mr. Eric Blasius Risser is President, Chief Executive Officer and Director at MacroGenics, Inc. since August 13, 2025. He served as Chief Operating Officer at MacroGenics, Inc. since February 22, 2022 unti...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Eric Risser	CEO, President & Director	less than a year	US$2.08m	0.12% € 300.3k
James Karrels	Senior VP & CFO	18yrs	US$1.15m	0.32% € 801.7k
Ezio Bonvini	Senior VP of Research & Chief Scientific Officer	9.7yrs	US$1.22m	0.23% € 567.3k
Thomas Spitznagel	Senior Vice President of Technical Operations	3.5yrs	US$1.88m	0.061% € 150.0k
Jeffrey Peters	Senior VP	8.9yrs	Veri yok	0.049% € 121.0k
Steve Harig	Senior Vice President of Human Resources	no data	Veri yok	Veri yok
Harish Krishnaswamy	Senior Vice President of Business Development & Portfolio Planning	less than a year	Veri yok	Veri yok
Frank Perabo	Vice President & Interim Head of Clinical Development	less than a year	Veri yok	Veri yok
Beth Smith	VP, Controller & Treasurer	1.5yrs	Veri yok	0.020% € 49.7k

2.5yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: M55 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Eric Risser	CEO, President & Director	less than a year	US$2.08m	0.12% € 300.3k
David Stump	Independent Director	12.7yrs	US$95.86k	0.023% € 57.4k
Federica O'Brien	Independent Director	5.3yrs	US$110.48k	0.023% € 57.4k
Edward Hurwitz	Independent Director	21.6yrs	US$85.86k	0.075% € 186.1k
Margaret Liu	Independent Director	3.3yrs	US$85.86k	0.023% € 57.4k
Scott Koenig	Director	24.7yrs	US$969.84k	1.36% € 3.4m
William Heiden	Independent Chairman of the Board	4yrs	US$145.03k	0.18% € 446.5k
Meenu Chhabra Karson	Independent Director	3.3yrs	US$80.22k	0.023% € 57.4k
Scott Jackson	Independent Director	9.3yrs	US$81.91k	0.023% € 57.4k
Jay Siegel	Independent Director	8.5yrs	US$106.28k	0.023% € 57.4k
Karen Jean Ferrante	Independent Director	9.3yrs	US$85.86k	0.023% € 57.4k

8.5yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: M55 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.5 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/25 03:16
Gün Sonu Hisse Fiyatı	2026/05/25 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

MacroGenics, Inc. 17 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Etzer Darout	Barclays
Peter Lawson	Barclays
Stephen V. Byrne	BofA Global Research

MacroGenics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

MacroGenics, Inc., Annual General Meeting, May 19, 2026

MacroGenics, Inc. Announces Departure of Stephen Eck, M.D., Ph.D., Senior Vice President, Clinical Development and Chief Medical Officer of the Company, Effective as of December 31, 2025

MacroGenics, Inc. Announces Executive and Board Changes, Effective August 13, 2025

MacroGenics, Inc., Annual General Meeting, May 21, 2025

Scott Koenig Intends to Step Down as Chief Executive Officer of MacroGenics, Inc., Early Next Year

Recent updates

Insufficient new directors

MacroGenics, Inc., Annual General Meeting, May 19, 2026

MacroGenics, Inc. Announces Pausing of Enrollment of New Study Participants in Linnet Trial

MacroGenics, Inc. Announces Departure of Stephen Eck, M.D., Ph.D., Senior Vice President, Clinical Development and Chief Medical Officer of the Company, Effective as of December 31, 2025

MacroGenics, Inc. Announces Executive and Board Changes, Effective August 13, 2025

MacroGenics, Inc.(NasdaqGS:MGNX) dropped from Russell 3000E Index

MacroGenics, Inc. to Report Q1, 2025 Results on May 13, 2025

MacroGenics, Inc., Annual General Meeting, May 21, 2025

MacroGenics, Inc. to Report Q4, 2024 Results on Mar 20, 2025

Third quarter 2024 earnings released: EPS: US$0.90 (vs US$0.28 in 3Q 2023)

Scott Koenig Intends to Step Down as Chief Executive Officer of MacroGenics, Inc., Early Next Year

MacroGenics, Inc. Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024

Second quarter 2024 earnings released: US$0.89 loss per share (vs US$0.93 profit in 2Q 2023)

Macrogenics Provides Vobramitamab Duocarmazine Update

MacroGenics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Block & Leviton Files Lawsuit Against MacroGenics, Inc

New major risk - Financial position

First quarter 2024 earnings released: US$0.84 loss per share (vs US$0.61 loss in 1Q 2023)

MacroGenics, Inc. Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

Full year 2023 earnings released: US$0.15 loss per share (vs US$1.95 loss in FY 2022)

Investor sentiment improves as stock rises 15%

MacroGenics, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Investor sentiment improves as stock rises 20%

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 21%

Third quarter 2023 earnings released: EPS: US$0.28 (vs US$0.40 loss in 3Q 2022)

MacroGenics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Insider recently bought €67k worth of stock

Investor sentiment deteriorates as stock falls 16%

New major risk - Share price stability

Second quarter 2023 earnings released: EPS: US$0.93 (vs US$0.67 loss in 2Q 2022)

MacroGenics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: US$0.61 loss per share (vs US$1.08 loss in 1Q 2022)

MacroGenics, Inc. to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings released: US$1.95 loss per share (vs US$3.37 loss in FY 2021)

Macrogenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients

MacroGenics, Inc. Appoints Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

Macrogenics, Inc. Approves the Appointment of Margaret Liu, M.D. to Serve as Director

MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab

Third quarter 2022 earnings released: US$0.40 loss per share (vs US$0.86 loss in 3Q 2021)

MacroGenics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: US$0.67 loss per share (vs US$0.67 loss in 2Q 2021)

MacroGenics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

MacroGenics, Inc. Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer

Senior VP recently bought €95k worth of stock

MacroGenics, Inc. Announces Management Changes

First quarter 2022 earnings released: US$1.08 loss per share (vs US$0.90 loss in 1Q 2021)

Insufficient new directors

MacroGenics, Inc. to Report Q1, 2022 Results on May 03, 2022

MacroGenics, Inc., Annual General Meeting, May 19, 2022

MacroGenics, Inc. Announces Promotion of Eric Risser to Chief Operating Officer

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

MacroGenics, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Third quarter 2021 earnings released: US$0.86 loss per share (vs US$0.66 loss in 3Q 2020)

MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA in Patients with HER2-Positive Metastatic Breast Cancer

Second quarter 2021 earnings released: US$0.67 loss per share (vs US$0.94 loss in 2Q 2020)

Insufficient new directors

MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting

First quarter 2021 earnings released: US$0.90 loss per share (vs US$0.91 loss in 1Q 2020)

Full year 2020 earnings released: US$2.47 loss per share (vs US$3.16 loss in FY 2019)

Revenue beats expectations

MacroGenics, Inc. Provides Update Proprietary Programs

New 90-day low: €16.00

MacroGenics, Inc. to Report Q4, 2020 Results on Feb 25, 2021

MacroGenics, Inc. Names Federica O’Brien to its Board of Directors

New 90-day low: €16.30

Macrogenics, Inc. Announces the Publication of Results from the Sophia Trial of Margenza

Macrogenics, Inc. Announces Research Collaboration and Global License Agreement to Develop Preclinical Bispecific Molecule with Janssen Biotech, Inc

MacroGenics, Inc. Announces FDA Approval of MARGENZA for Patients with Pretreated Metastatic HER2-Positive Breast Cancer